Summary[1] edit edit source
GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. Its technology platform enables glycan-directed cancer therapy and analytical tools for glycosylation. The company develops GNX102, a humanized antibody for cancer; and GNX201, GNX202, GNX203, and GNX204 for various solid tumors. It also develops Denosumab, a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and Aflibercept, a vascular endothelial growth factor binding fusion protein for the treatment of ophthalmology and oncology. GlycoNex Incorporation was founded in 2001 and is based in New Taipei City, Taiwan.
References and notes edit edit source
- ↑ Source: Yahoo Finance.